Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective

Marino, Luca; Concistrè, Antonio; Suppa, M; Galardo, Gioacchino; Rosa, Antonello; Bertazzoni, Giuliano; Pugliese, Francesco; Letizia, Claudio; Petramala, Luigi

doi:10.3390/ijms23158230

Cited by 9 publications

(9 citation statements)

References 42 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intracellular and transmembrane domains are absent from the soluble ST2 isoform (sST2) [124][125][126]. sST2 is a novel biomarker and has been added to the 2013 ACCF/AHA guideline to risk stratify patients with HF [127].…”

Section: Sst2mentioning

confidence: 99%

“…Improves survival and hospital stay [139]. Easily accessible diagnostic methods [140] + At a threshold of 100 pg/mL [29], sensitivity of 90% and specificity of 76% NT-proBNP + At a cutoff level of 300 pg/mL [30], sensitivity of 90% and specificity of 85% + [145] Limited evidence supporting sensitivity and specificity sST2 + Risk stratification [127]. Predictive of all-cause deaths and CVS-related deaths [135] + [133] Limited evidence supporting sensitivity and specificity…”

Section: Sst2mentioning

confidence: 99%

See 1 more Smart Citation

Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review

Kayani,

Fatima,

Yarra

et al. 2024

Cureus

View full text Add to dashboard Cite

Heart failure (HF) represents a significant global health challenge, characterized by a variety of symptoms resulting from cardiac dysfunction. This dysfunction often leads to systemic and pulmonary congestion. The pathophysiology of HF is complex, involving stimulation of the sympathetic nervous system, which is insufficiently balanced by the release of natriuretic peptide. This imbalance leads to progressive hypertrophy and dilatation of the heart’s chambers, impairing its pumping efficiency and increasing the risk of arrhythmias and conduction disorders. The prevalence of HF is exceptionally high in industrialized nations and is expected to increase owing to an aging population and advancements in diagnostic methods. This study emphasizes the critical role of early diagnosis in reducing morbidity and mortality associated with HF, focusing specifically on the evolving importance of biomarkers in managing this condition. Biomarkers have played a key role in transforming the diagnosis and treatment of HF. Traditional biomarkers such as b-type natriuretic peptide and N-terminal pro-b-type natriuretic peptide have been widely adopted for their cost-effectiveness and ease of access. However, the rise of novel biomarkers such as growth differentiation factor 15 and adrenomedullin has shown promising results, offering superior sensitivity and specificity. These new biomarkers enhance diagnostic accuracy, risk stratification, and prognostic evaluation in HF patients. Despite these advancements, challenges remain, such as limited availability, high costs, and the need for further validation in diverse patient populations. Through a comprehensive literature review across databases such as PubMed, Google Scholar, and the Cochrane Library, this study compiles and analyzes data from 18 relevant studies, offering a detailed understanding of the current state of HF biomarkers. The study examines both traditional and emerging biomarkers such as galectin-3 and soluble suppression of tumorigenicity 2 in HF, exploring their clinical roles and impact on patient outcomes.

show abstract

Section: Sst2mentioning

confidence: 99%

Section: Sst2mentioning

confidence: 99%

Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review

Kayani,

Fatima,

Yarra

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…[91,92] Focusing on CVDs, international guidelines and studies on large populations suggest that, beyond its limited use on HF diagnosis compared to other biomarkers (i.e., pro-BNP, hs-CRP, and hs-TnT), the evaluation of sST2 is very helpful in correlation to clinical data, especially on the severity of the underlying cardiomyopathy, left ventricular hypertrophy, cardiac remodeling, ejection fraction, NYHA score, and finally to obtain prognostic information. [93] Some research findings show unusually higher sST2 levels in individuals who tested positive for SARS-CoV-2 infection without exhibiting CV comorbidities, which raised the possibility that ST2 may serve as a dual cardio-inflammatory biomarker. [94] In the group with acute HF, the blood levels of all examined biomarkers (sST2, NT-proBNP, cardiac troponin) are considerably greater.…”

Section: Interferonmentioning

confidence: 99%

A critical review on brain and heart axis response in COVID‐19 patients: Molecular mechanisms, mediators, biomarkers, and therapeutics

Abha Mishra,

Podili,

Pathlavath

et al. 2023

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Since the outbreak of highly virulent coronaviruses, significant interest was assessed to the brain and heart axis (BHA) in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐affected patients. The majority of clinical reports accounted for unusual symptoms associated with SARS‐CoV‐2 infections which are of the neurological type, such as headache, nausea, dysgeusia, anosmia, and cerebral infarction. The SARS‐CoV‐2 enters the cells through the angiotensin‐converting enzyme (ACE‐2) receptor. Patients with prior cardiovascular disease (CVD) have a higher risk of COVID‐19 infection and it has related to various cardiovascular (CV) complications. Infected patients with pre‐existing CVDs are also particularly exposed to critical health outcomes. Overall, COVID‐19 affected patients admitted to intensive care units (ICU) and exposed to stressful environmental constraints, featured with a cluster of neurological and CV complications. In this review, we summarized the main contributions in the literature on how SARS‐CoV‐2 could interfere with the BHA and its role in affecting multiorgan disorders. Specifically, the central nervous system involvement, mainly in relation to CV alterations in COVID‐19‐affected patients, is considered. This review also emphasizes the biomarkers and therapy options for COVID‐19 patients presenting with CV problems.

show abstract

“…30 IL-33 and its receptor sST2 are thought to be independent predictors possibly associated with poor prognosis for heart failure. 31,32…”

Section: The Receptor Of Il-33mentioning

confidence: 99%

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Jiang,

Jin,

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is believed to play important roles in different diseases by binding to its specific receptor suppression of tumorigenicity 2 (ST2). In the heart, IL-33 is expressed in different cells including cardiomyocytes, fibroblasts, endothelium, and epithelium. Although many studies have been devoted to investigating the effects of IL-33 on heart diseases, its roles in myocardial injuries remain obscure, and thus further studies are mandatory to unravel the underlying molecular mechanisms. We highlighted the current knowledge of the molecular and cellular characteristics of IL-33 and then summarized its major roles in different myocardial injuries, mainly focusing on infection, heart transplantation, coronary atherosclerosis, myocardial infarction, and diabetic cardiomyopathy. This narrative review will summarize current understanding and insights regarding the implications of IL-33 in cardiac diseases and its diagnostic and therapeutic potential for cardiac disease management.

show abstract

Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective

Cited by 9 publications

References 42 publications

Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review

Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review

A critical review on brain and heart axis response in COVID‐19 patients: Molecular mechanisms, mediators, biomarkers, and therapeutics

Roles of IL-33 in the Pathogenesis of Cardiac Disorders

Contact Info

Product

Resources

About